Signal mining and analysis of adverse drug event signals of darolutamide
- VernacularTitle:达罗他胺ADE信号的挖掘与分析
- Author:
Lijuan QIAO
1
;
Jinhua CHEN
2
;
Jian KANG
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Zhengzhou University，Zhengzhou 450052，China
2. Dept. of Pharmacy，the Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital，Zhengzhou 450008，China
- Publication Type:Journal Article
- Keywords:
darolutamide;
FDA adverse event reporting system;
report odds ratio;
proportional reporting ratio;
signal mining
- From:
China Pharmacy
2024;35(3):339-342
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore and analyze the adverse drug event （ADE） signals of darolutamide and provide a reference for its clinical safe use. METHODS ADEs related to darotamide were collected based on the US FDA adverse event reporting system （FAERS） database from the third quarter of 2019 to the third quarter of 2022. Data mining and analysis were conducted by the report odds ratio （ROR） and proportional reporting ratio （PRR） methods. RESULTS A total of 565 ADE reports related to darolutamide were extracted， 356 ADE reports about darolutamide as the primary suspected drug were included， 38 ADE signals with darolutamide as the primary suspected drug were excavated， involving 15 system organ class （SOC）， mainly concentrated in patients over 65 years old. The SOC of darotamide ADE signal mainly focused on various examinations， systemic diseases and various reactions at the administration site， benign/malignant tumors or those with unknown nature （including cystic and polypoid）， kidney and urinary system diseases. A total of 13 ADE signals not mentioned in the instructions included increased prostate-specific antigen， dysphagia， cognitive impairment， erectile dysfunction， rhabdomyolysis， gynecomastia and decreased platelet count， etc. CONCLUSIONS When using darolutamide， in addition to ADE in the drug instruction， we should pay close attention to potential ADE， such as increased prostate-specific antigen， rhabdomyolysis， gynecomastia and decreased platelet count， so as to avoid drug withdrawal or organ damage caused by ADE.
